Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania (PMAL03)

This study has been completed.

Sponsor:

Collaborators:

Mymetics Corporation

Pevion Biotech Ltd

Information provided by (Responsible Party):

Swiss Tropical & Public Health Institute

ClinicalTrials.gov Identifier:

NCT00513669

First received: August 8, 2007

Last updated: March 14, 2013

Last verified: March 2013

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	March 2009
Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

No publications provided by Swiss Tropical & Public Health Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Cech PG, Aebi T, Abdallah MS, Mpina M, Machunda EB, Westerfeld N, Stoffel SA, Zurbriggen R, Pluschke G, Tanner M, Daubenberger C, Genton B, Abdulla S. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One. 2011;6(7):e22273. Epub 2011 Jul 22.

To Top